Resolution:
## Figure 1.
Disposition of patients. Studies 06–008 and 06–009 were concurrent phase 3, double-blind, placebo-controlled,
clinical trials; 06–010 is the open-label extension of the phase 3 trials. The denominator
for studies 06–008 and 06–009 is the number of randomized patients, and the denominator
for 06–010 is the number of treated patients. *Denominator is the number of completed
patients from 06–008/06–009. PBO, placebo; SXB, sodium oxybate.
Spaeth |